Clinical trial
Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
NCT00024570 · INSYS Therapeutics Inc, Industry · Completed
Key facts
| NCT number | NCT00024570 |
|---|---|
| Title | Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma |
| Official title | Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma: Phase I/II Study |
| Lead sponsor | INSYS Therapeutics Inc, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma |
| Intervention type | Drug, Procedure |
| Interventions | IL13-PE38QQR, targeted fusion protein therapy, surgery |
| Enrollment | 60 |
| Start date | Nov 1, 2000 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Sep 21, 2001 |
| Last update posted | Nov 14, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: